MedTrace Logo

Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive

NCT03790397 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 169

Last updated 2022-06-03

No results posted yet for this study

Summary

This is a retrospective, multicenter and observational study of Osimertinib monotherapy treatment in Subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M mutation-positive who have received the treatment within the Special Use Medication Program (SUMP) in Spain.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Osimertinib

Patients treated with Osimertinib within the Special Use medication Program (SUMP).

Sponsors & Collaborators

  • Fundación GECP

    lead OTHER

Principal Investigators

  • Mariano Provencio, MD · Hospital Universitario Puerta de Hierro

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-26
Primary Completion
2019-07-15
Completion
2020-04-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03790397 on ClinicalTrials.gov